Ophthalmic Drug Delivery System-A Concise Review on its Conventional and Novel Approaches
The main aim of this review is to focus on the various kinds of approaches which are used in ophthalmic drug delivery. Ophthalmic drug delivery system is used to treat various conditions associated with eye. The main purpose of a formulation designer is to formulate an eye formulation which could reside in the eye in an optimum concentration and for a proper duration for its proper effect. The main problem seen in the conventional dosage forms is their poor bioavailability due to fast precorneal drug loss primarily due to nasolacrimal drainage. The residence time of conventional formulations is also very less in the eye resulting into minimal advantages. In order to combat all these problems, now days the pharmaceutical scientists are very much involved in the research towards the novel approaches of ophthalmic drug delivery. The present paper enlists the important novel formulations which have been developed recently and explore their various advantages over conventional forms.
2. Macha S, Mitra AK. Ophthalmic drug delivery systems: second edition revised and expanded. (2003). Chapter 1, Overview of Ocular Drug Delivery (pp 1-3).New York: Marcel Dekker, Inc.
3. Venkata RG, Madhavi S, Rajesh P. Ocular Drug Delivery: An Update Review. International Journal Of Pharmacy and Biological Sciences. 2011; 1(4):437-446.
4. Patel PB, Shastri DH, Shelat PK, Shukla AK. Ophthalmic Drug Delivery System: Challenges and Approaches. Systematic Reviews in Pharmacy. 2010; 1(2):113-115.
5. Sikandar MK, Sharma PK, Visht S. Ocular Drug Delivery System: An Overview. International Journal of Pharmaceutical Sciences and Research.2011; 2 (5):1168-175.
6. Preethi GB, Prashanth K. Design and Evaluation of Controlled- Release Ocular Inserts of Brimonidine-Tartrate and Timolol Maleate. International Journal of Pharmacy and Pharmaceutical Sciences. 2017; 9(1):79-82.
7. Retamal MA, Leon Paravic CG, Verdugo CA, Alcaino CA, Moraga Amaro R. Connexin in Lens Physiology and Cataract Formation. Journal of Clinical and Experimental Ophthalmology.2011;1(2):1-13.
8. Duong HQ, Westfield KC, Singleton IC. Comparing Three Post-Op Regiments for Management of Inflammation Post Uncomplicated Cataract Surgery. “Are Steroids Really Necessary?”. Journal of Clinical and Experimental Ophthalmology. 2011; 2:163-164.
9. Srilatha.B. A review on Age Related Eye Diseases and their Preventive Measures. Journal of Clinical & Experimental Ophthalmology. 2011; 2(12):1-5.
10. Bhagat N, Tu Y, Zarbin MA. A Case of Vortex Vein Aplasia and Recurrent Idiopathic Uveal Effusion Syndrome. Journal of Clinical and Experiment Ophthalmology. 2011; 2(1):1-3.
11. Yoon KC, Kim KK. “Is Combined Photodynamic Therapy and Subconjunctival Bevacizumab Injection Useful for Corneal Neovascularization?”. Journal of Clinical and Experimental Ophthalmology. 2011; 2(1):1-4.
12. Dhanapal R, Ratna Vijaya J. Ocular Drug Delivery System – A Review. International Journal of Innovative Drug Discovery. 2012; 2(1): 4-15.
13. Brown A, Addison B. Eye disorders: understanding the causes, symptoms and management. The Pharmaceutical Journal. 2017; 2:1-17.
14. Mahalingam P, Kumar S. To study the incidence of endophthalmitis after manual small incision cataract surgery in a tertiary eye care center. Journal of Clinical Ophthalmology and Research.2013; 1(3):147-150.
15. Agrawal A, Yadav KL, Rathour V. Ocular Drug Delivery System & Role of Ocular Inserts in Eye Disorder Treatment: A Review. Asian Journal of Pharmaceutical Technology and Innovation.2016; 4(21):45- 54.
16. Yusuf A, Lehmussaari K. Industrial Perspective in Ocular Drug Delivery. Advanced Drug Delivery Reviews. 2006; 58:1258-1268.
17. Sultana Y, Jain R, Aqil M, Ali A. Review of ocular drug delivery. Current drug Delivery.2006; 3: 207-217.
18. Wen-Di M, Hui X, Chao W, Shu-Fang N, Wei-San P. Pluronic F127- Poly acrylic acid copolymers as in situ gelling vehicle for ophthalmic drug delivery system. International Journal of Pharmaceutics.2008; 35:247-256.
19. Nirmal HB, Bakliwal SR, Pawar SP. In Situ gel: New trends in Controlled and Sustained Drug Delivery System. International Journal of Pharmaceutical Technology and Research. 2010; 2(2):123-127.
20. Saini N, Kumar D. An Insight to ophthalmic drug delivery system. International Journal of Pharmaceutical Studies and Research. 2012; 3(2): 9-13.
21. Makwana SB, Patel VA, Parmar SJ. Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results in Pharma Sciences. 2016; 6:1-6
22. Lerman S, Davis P, Jackson WB. Prolonged release hydrocortisone therapy. Canadian Journal of Ophthalmology. 1973; 8: 114 -118.
23. La Motte J, Grossman E, Hersch J. The efficacy of cellulosic ophthalmic inserts for treatment of dry eye. Journal of American Ophthalmologic Association. 1985; 56: 298-302.
24. Swanson AA, Jeter DJ, Tucker P. Ophthalmic vehicles II, Comparison of ointment and polyvinyl alcohol 1.4%. Ophthalmologic. 1970; 160:265- 70.
25. Nanjawade BK, Manvi FV, Manjappa AS. In Situ-forming hydrogels for sustained ophthalmic drug delivery. Journal of Controlled Release. 2007; 126:119-34.
26. Schaeffer HE, Brietfelter JM, Krohn DL. Vesicular systems: An overview. Investigative Ophthalmology and Visual Science. 1982; 23:530.
27. Ansari MJ, Kohli K, Dixit N. Microemulsions as potential drug delivery systems: A review. Journal of Pharmaceutical Science and Technology. 2008; 62:66-79.
28. Kaur A, Seth N, Rana AC, Harikumar SI. Ocular Implants: A Novel Approach To Ocular Drug Delivery. International. Journal of Drug Formulation and Research. 2011; 2(5): 93-95.
29. Walter LZ, Timothy RS. Ophthalmic Drug Therapy – Challenges and Advances in Front of the-Eye Delivery. Mystic Pharmaceuticals Inclusive. 2007; 2:44-45.
30. Weiner A, Sinnett K, Johnson S. Tack for intraocular drug delivery and method for inserting and removing the same.1995, US Patent 5466233.
31. Yung‐Chi L, Jeffrey W. Design and evaluation of the ocular insert containing phenyl‐epicene and tropicamide to improve and enhance the bioavailability of the drug. International Journal of Pharmaceutical Science.1999; 182:121‐126.
32. http://www.ondrugdelivery.com/publications/82/Issue_82.htm accessed on 17/12/2018.
33. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2009; 90(3):262-267.
34. Soni AD, Shah S, Patel K. Innovation In Ocular Drug Delivery System. World Journal of Pharmaceutical Research. 2018; 7(1):389-406.
35. Kurniawansyah IS , Rahmi F, Sopyan I. pH Triggered In-situ Gelling Ophthalmic Drug Delivery System. International Journal of Drug Delivery Technology. 2018; 8(1):1-5.
36. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics Journal. 2017; 9(12):1-33